Paper Details

  1. Home
  2. Paper Details

A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.

Author: IsmailM, MohamedW A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Bosentan demonstrated significant efficacy as an adjuvant therapy for persistent pulmonary hypertension of the newborn (PPHN), leading to a favorable outcome in 87.5% of treated patients compared to 20% in the placebo group. Bosentan was well tolerated, with no drug-related adverse events observed.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the efficacy and safety of bosentan as an adjuvant therapy of persistent pulmonary hypertension of the newborn (PPHN). STUDY DESIGN: Forty-seven neonates with PPHN were randomly assigned to receive either bosentan (n=24) or placebo (n=23). Efficacy was evaluated with a favorabl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/jp.2011.157

データ提供：米国国立医学図書館（NLM）

Bosentan: A Potential Treatment for Persistent Pulmonary Hypertension of the Newborn

Persistent pulmonary hypertension of the newborn (PPHN) is a serious condition that can affect infants. This study investigates the effectiveness and safety of bosentan as an adjuvant therapy for PPHN. The researchers conducted a randomized controlled trial, comparing bosentan treatment to placebo, and evaluated outcomes based on factors like oxygenation index and pulmonary artery pressure.

Bosentan's Effectiveness: A Light in the Tunnel

The study found that bosentan treatment significantly improved outcomes for infants with PPHN compared to placebo, demonstrating a statistically significant difference. Furthermore, the researchers reported no drug-related adverse events, suggesting that bosentan might be a safe and effective treatment option for this condition.

Bosentan's Impact: Hope for Tiny Patients

This study provides promising evidence for the potential of bosentan as an adjuvant therapy for PPHN. However, further research is needed to confirm its long-term effects and optimize its use in clinical practice.

Dr. Camel's Conclusion

Imagine a newborn struggling to breathe like a desert wind caught in a sandstorm. Bosentan, like a calming oasis, helps ease their suffering. This research offers a ray of hope for infants with PPHN, potentially improving their chances of survival and growth.

Date :
  1. Date Completed 2013-05-29
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22076415

DOI: Digital Object Identifier

10.1038/jp.2011.157

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.